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Drug-resistanceTuberculosis is explicitly recognized as a major global public health problem. In Coˆte d’Ivo-
ire, relapse cases represent 66.5% of patients eligible for retreatment according to the
National Tuberculosis Control Program. This study objective was to detect multidrug-resis-
tance tuberculosis among relapse cases. Patients were recruited in tuberculosis centers in
routine. A standardized questioning was administrated. Two sputum samples were col-
lected and transported at Institut Pasteur. Sputum samples were decontaminated by NALC
method. The DNA extraction was realized with 500 ll of decontaminated sputum sample
with smear-positive. MTBDRplus assay version 2.0 was performed according to the manu-
facturer’s instruction. An internal quality control program with positive and negative con-
trols was implemented for interpretation of results. In total 146 relapse cases with smear
positive were studied. Out of selected patients, 130 had received the 2RHZE/4RH regimen
and 16, the 2RHZES/1RHZE/5HRE. In group of relapse cases previously treated with
2RHZE/4RH regimen, 40 (31.3%, IC95%: [0.23; 0.39]) had punctual mutations at codon 526
in rpoB gene. Although, in patients under treated with 2RHZES/1RHZE/5HRE, a mutation
in rpoB gene was identified in 12 of 16 sputum samples. Thirteen mutations conferring a
resistance to Isoniazid were observed of which 9 in katG gene and 4 in katG and promoter
region of inhA gene. The comparison (Chi-square with Yates correction) of resistance rates
to Rifampin estimated showed a statistically significant difference.
Conclusion: Use of a rapid method to detect drug-resistance in recurrent TB cases has per-
mitted to identify patients eligible for first-line drugs or not.
 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
Tuberculosis (TB) is a disease that affects the whole society
and its drug-resistant form adds another obstacle to itscontrol. Rapid diagnosis of TB and multidrug-resistant (resis-
tance to at least Rifampin and Isoniazid) TB (MDR-TB) is an
important challenge to ensure a quick and adequate course
of TB therapy is initiated to limit the dissemination ofed.
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nerstones of first-line drugs used for the treatment of TB.
With DNA fingerprinting, the cases of recurrent TB can be
categorized as relapse cases due to the original infecting
strain or reinfection with a new strain of Mycobacterium tuber-
culosis [2]. Considering that recurrent TB cases are also the
previously treated patients for TB, they are consequently a
group with high risk for MDR-TB [3].
At the operational level, the recurrent TB cases are often
identified as relapse cases. In fact, a relapse case is a patient
previously declared cured or treatment completed and subse-
quently diagnosed with a new episode of TB bacteriologically
confirmed (sputum smear or culture) [4]. The emergence of
MDR-TB associated with relapse may be considered as an
additional challenge in TB control [5,6], notably in developing
countries. The prevalence of MDR-TB has been estimated to
be low in sub-Saharan Africa, where surveillance of drug
resistance is limited [1]. In Coˆte d’Ivoire, the prevalence of
MDR-TB cases among new cases with a positive smear de-
creased from 5.3% to 2.5%, respectively from 1995 to 2006 [6].
These last 10 years, relapse cases represented 66.5% of
retreatment cases notified by the National Tuberculosis Con-
trol Program. Relapse cases may be to a certain extent assim-
ilated with new TB cases. Also, there is limited data available
for the principal two first-line drugs in Coˆte d’Ivoire concern-
ing relapse cases.
New diagnostic tools for TB were developed and validated,
particularly molecular methods [7,8]. Molecular methods are
highly efficient for Rifampin resistance detection and are well
adapted to search for the most relevant Isoniazid resistance.
Some methods require minimal infrastructure and equip-
ment [9].
The study objective was to detect resistance to Rifampin
and Isoniazid among relapse cases diagnosed in TB centers
in Coˆte d’Ivoire.
Patients and methods
Study sites
Patients were recruited from the Pneumology service of CHU
de Cocody and also referrals from regional centers for TB in
Coˆte d’Ivoire. In a sanitary pyramid, the pneumology service
is at the central level, and the regional centers are at the inter-
mediate level. A standard questionnaire was administered by
trained medical staff. Symptomatic patients were included
consecutively based on their history [4]. Data collected in-
cluded age, gender, previous anti-TB treatment, episodes of
TB and results of their smears for AFB detection after Ziehl-
Neelsen staining.
Samples collection and transport
For each patient enrolled, two sputum samples (spot, early
morning) were collected and put in individual bags. Samples
collected were transported at 4 C in the icebox from the
study site to the National Reference Laboratory for Tuberculo-
sis. This laboratory is integrated in the Mycobacteria Unit of
Institut Pasteur de Coˆte d’Ivoire.Resistance detection
DNA extraction
Sputum samples were processed using the US Centers for
Disease Control and Prevention (US CDC) recommended
method of N-acetyl-L-Cysteine 4% NaOH-2.9% Citrate. Five
milliliters of sputum were transferred in 50 ml of plastic cen-
trifuge tube. Five milliliters of NALC solution were added to
the sputum. The preparation was mixed by vortexing for
1 min and incubated at room temperature for 15 min. In
the centrifuge tube, 35 ml of sterile phosphate buffer pH
6.8 were added and centrifuged at 3.000g for 20 min. Super-
natant was carefully eliminated. Pellet was re-suspended
with 2 ml of sterile phosphate buffer; 200 ll of re-suspended
pellet were used to perform a smear which was stained
using the Ziehl-Neelsen method.
The ‘‘GenoLyse’’ kit was used for bacterial DNA extrac-
tion; 500 microliters of sediment were transferred in an
eppendorf tube of 1500 ll. The suspension was centrifuged
at 10.000g in an aerosol-tight rotor for 15 min. The superna-
tant was discarded; 100 ll of lysis buffer were added to the
sediments. The bacterial preparation was homogenized by
vortexing. The bacterial suspension was inactivated at 95 C
for 5 min; 100 ll of neutralization buffer were added to the
preparation. The inactivated suspension was centrifuged at
13.000g for 5 min. The DNA contained in the supernatant
was transferred to a fresh tube. A negative control was in-
cluded in each run of sputum sample decontaminated for
DNA extraction.
Amplification of DNA extracted from sputum samples
With sputum containing AFB, Genotype MTBDR assay version
2.0 (Hain Lifescience, Nehren, Germany) was performed as
recommended by the manufacturer. The amplification mix-
ture contained 35 ll of primer-nucleotide Mix B, 10 ll of Mix
A (5 ll 10· PCR buffer, 2 ll of MgCl2, 3 ll of molecular water,
1 unit of thermostable Taq DNA polymerase) and 5 ll of ex-
tracted chromosomal DNA solution.
Amplification parameters used were: 15 min of denatur-
ation at 95 C, followed by 20 cycles of 30 s at 95 C and
2 min at 65 C, followed by 30 additional cycles of 25 s at
95 C, 40 s at 53 C, and 40 s at 70 C, ending with a final exten-
sion step of 8 min at 70 C (1 cycle).
Prior to hybridization, a migration of 5 ll of each PCR prod-
uct was performed during 30 min at 100 V in 1% agarose gel
stained with ethidium bromide. DNA amplified was revealed
with a UV-transilluminator lamp (wave’s length 365 nm).
Hybridization
Hybridization and detection were performed with a TwinCu-
bator semi-automated washing and shaking device according
to the manufacturer’s instructions and using the reagents
provided with the kit. Twenty microliters of denaturation
solution was mixed with 20 ll of amplified sample. The mixed
solution was incubated at room temperature for 5 min. One
milliliter of pre-warmed hybridization buffer was added be-
fore the membrane strips were placed and shaken in the
hybridization solution for 30 min at 45 C. After two washing
steps, a colorimetric detection of the hybridized amplicons
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phosphatase conjugate.
An internal quality control program with positive and neg-
ative controls was implemented during the study. An inter-
pretable MTBDRplus assay was defined as a test strip with
all control markers positive, including results of the markers
for positive control (H37Rv strain), negative control for DNA
extraction and for mix preparation.
Statistical tests
Data were entered in the MS Excel 8.0 and analyzed using Epi-
info 6.04 (CDC, Atlanta). The rate of resistance to Rifampin
and Isoniazid in each category of patients recruited with
95% Confidence Interval (CI) was estimated. The rates ob-
tained were compared using Chi-square testing.
Results
A total of 146 relapse cases with positive smear were selected.
After the analysis of PCR products with a UV-transilluminator
lamp, all were definitively enrolled into the study. Among
these 146 patients, 130 had received the 2RHZE/4RH regimen
and 16 the 2RHZES/1RHZE/5HRE regimen. The internal con-
trol quality results were concordant with expected results. In-
deed, the negative control included in each serial of DNA
extraction was negative for detection of DNA amplified. The
negative and positive controls of each testing run have been
also respectively positive and negative (Fig. 1).
In the group of relapse cases previously treated with
2RHZE/4RH regimen, analysis of the sputum samples revealed
40 (31.3%, IC95%: [0.23; 0.39]) punctual mutations in rpoB gene.
Most of them occurred at codon 526. Two cases of double
mutation in this gene were observed in 2 sputum samples.Fig. 1 – Revelation of PCR products after migration. Legend:
lines 1, 14, A and N: molecular weight marker (100 pb). Lines
from 2 to 13 and from B to J amplified DNA of sputum
samples. Line K: negative control for mix preparation. Line
L: negative control for DNA extraction. Line M: positive
control (H37rv).A S315T mutation (katG gene) was observed in 29 sputum
samples of recruited patients. A mutation in katG gene asso-
ciated with a mutation in the promoter region was described
in the sputum of 13 patients. Among the 130 sputum samples
analyzed, 39 (30.5%) had a simultaneous mutation in rpoB and
katG genes (Table 1).
In the second group of patients (treated with 2RHZES/
1RHZE/5HRE), a mutation in the rpoB gene was identified in
12 of the 16 sputum samples analyzed. Thirteen mutations
conferring a resistance to Isoniazid were observed, of which
9 in the katG gene and 4 in the katG and promoter region of
the inhA gene. Among 15 sputum samples analyzed and vali-
dated, 10 (66.7%) had a mutation in the rpoB gene associated
with a mutation in one of the two genes (katG gene, inhA pro-
moter region). Among these 15 sputum samples, 2 had no
mutation in the genes explored (Table 1).
The comparison (Chi-square testing with Yates correction)
of resistance rates to Rifampin estimated from sputum sam-
ples in the two groups of relapse cases showed a statistically
significant difference (Table 2).Discussion
At the operational level of the sanitary pyramid, a patient
treated for TB and declared ‘‘cured’’ or ‘‘treatment completed’’
that presents with a new episode of TB confirmed bacteriolog-
ically is considered a relapse case [4]. From the bacteriological
point of view, this new episode of TB can be due to an infec-
tion with the strain of the first episode or by re-infection with
a new strain of M. tuberculosis Complex.
Relapse cases or recurrence TB cases [10] represent a group
of patients who have a risk for drug resistances and MDR-TB
[11]. An efficient tool is required for identification of MDR-TB
cases. In most countries, effective control of drug-resistant TB
requires the rapid detection of drug strains followed by
prompt implementation of an adequate anti-TB therapy
based on laboratory findings. This is a challenge for National
Tuberculosis Control Programs notably in developing coun-
tries. Although performances of the molecular assay have
not been estimated in this study, the method used has been
developed and evaluated for use with M. tuberculosis cultures
and smear-positive specimens [12,13]. In different TB labora-
tories, evaluations of this molecular method showed differ-
ences in terms of susceptibility and specificity [7,12,13]. In
Africa, some studies were realized. Results of evaluation di-
rectly from sputum samples in Uganda [14] revealed a sensi-
tivity of 100% and 96.1% of specificity for detection of
Rifampin resistance. For Isoniazid resistance, sensitivity and
specificity were respectively 80.8% and 100.0%.
Despite the precautions taken, two cases of hybridization
were uninterpretable (Table 2). Analysis of laboratory data
(date of DNA extraction, DNA migration and revelation, line
probe assay results obtained. . .), notably for the double muta-
tion obtained at the 526 codon combined with internal quality
control results obtained for each run of DNA extraction, mix
preparation, and hybridization have shown that these results
were due to contamination of DNA contained in the tube dur-
ing the process of DNA extraction [15]. Error occurred during
transfer of DNA into a fresh tube. This kind of contamination
Table 1 – Results of Rifampin and Isoniazid susceptibility detection in sputum samples.
Relapse after regimen
Mutations 2RHZE/4RH RHZES/1RHZE/5HRE
n = 130 n = 16
rpoB
rpoBMut1 10 2
rpoBMut2A 11 1
rpoBMut2B 9 4
rpoBMut3 10 4
rpoB Mut1 + rpoBMut2B 1 –
rpoB Mut2A + rpoBMut2B 1a 1a
rpoB wild type 88 4
katG
katG Mut1 29 9
katG wild type 88 3
inhA promoter region
inhA Mut1 – –
inhA Mut2 – –
inhA Mut3A – –
inhA Mut3B – –
inhA wild type 117 12
Associated mutations
katG Mut1 + inhA Mut3A 8 4
katG Mut1 + inhA Mut3B 5 –
a Mutations concerning the same codon.
Table 2 – Comparison of mutation rate observed in the categories of relapses for rpoB gene.
Mutation in rpoB 2RHZE/4RH 2RHZES/1RHZE/5HRE
n = 128 n = 15
Presence of one mutation 40 11
Absence of mutation 88 4
Chi-square testing with Yates correction: 8.61 p value = 0.0003.
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method used seems most adapted for laboratories at the cen-
tral level.
A previous treatment for TB is a risk factor associated with
drug-resistant Mycobacterium [11]. Indeed, some studies
showed a high rate of MDR-TB cases estimated at 12.1% and
9.2% in patients previously treated in Uganda and Gujarat (In-
dia), respectively [3,16].
In this study, all MDR-TB cases detected were previously
treated with only first-line drugs. For relapse cases who had
received the 2RHZE/4RH regimen, 39 (30.5%) among the 128
patients with validated results were MDR-TB cases.
In Vietnam, Quy et al. have shown that among relapse
cases, none had primary resistance. The MDR-TB cases esti-
mated to 8% in their study were acquired. Consequently, these
cases were probably due to infection with a new strain. [17].
The rate of MDR-TB cases observed in relapse cases after
the 2RHZES/1RHZE/5HRE regimen was twice as important as
the one of the group treated with 2RHZE/4RH. The difference
observed between these two groups may be explained by
antecedents of treatment of the patients who received the
retreatment regimen [11].The MDR-TB rates observed are high in recurrent TB cases.
In this setting, Directly Observed Therapy (DOT) must be im-
proved for reducing the dissemination of strains as one of the
principal sources of re-infection in recurrent TB cases [18].
These efforts must also be sustained by an improvement in
the social and economic context (housing, well-being, public
transport. . .).
In this study, the molecular method used has permitted
the detection of one case of infection with two strains. In-
deed, the eight probes which detect a mutation in the rpoB
gene were hybridized and revealed (Table 2). It is not clearly
established that this observation is due to mixed infection.
In the endemic context of TB, mixed infection is not excep-
tional, but it must be well documented [19], notably in previ-
ous patients treated for TB.
Conclusion
Use of a rapid method to detect drug-resistance in recurrent
TB cases has allowed for an estimate of multidrug-resistant
TB and clearly identifies patients eligible for first-line drugs
or not.
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